Alarming Rise in Breast and Cervical Cancers in Low- and Middle-Income Countries: Breaking Down Screening Barriers

By HEOR Staff Writer

July 5, 2023

Breast and cervical cancers are on the rise in low- and middle-income countries, with lower cure rates due to late diagnosis. Screening programs in these countries are not comprehensive, hindering early detection. 

By analysing studies published between 2016 and 2021, articles from low- and middle-income countries and using the 5A framework (approachability, acceptability, availability, affordability, and appropriateness), screening barriers were classified. 

Findings highlighted the lack of awareness, high screening costs, and distance to screening centers as major obstacles. Embarrassment, fear, and cultural factors also contribute to low screening rates. 

To combat these challenges, policymakers and governments must take action to enhance public confidence in healthcare systems. Evidence-based strategies are needed to educate women about cancer causes and risk factors, promoting increased adherence to screening. Together, we can make a difference in the fight against breast and cervical cancers worldwide.

Reference url

Recent Posts

HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC

By HEOR Staff Writer

March 2, 2026

FDA Greenlights HERNEXEOS Lung Cancer Treatment as First-Line Option HERNEXEOS lung cancer treatment (zongertinib tablets), developed by
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 Trial Results
KEYTRUDA Padcev MIBC Survival Breakthrough in Cisplatin-Eligible Patients KEYTRUDA Padcev MIBC Survival benefits shone in the Phase 3 KEYNOTE-B15 trial, where perioperative KEYTRUDA (pembrolizumab) plus Padce...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercial Execution

By HEOR Staff Writer

February 24, 2026

Merck's portfolio optimization strategy includes reorganizing its Human Health division into two focused business units—Oncology and Specialty, Pharma & Infectious Diseases—to sharpen commercial execution across its growing pipeline. This